MSCC believes that Australia is well placed to become a leader in stem cell therapy research. This creates a unique opportunity for MSCC to become a world leader in stem cell research and therapy.
Osteoarthritis is the 4th leading cause of disability across the world. Recognising this, the primary objective for any management strategy is to improve pain and function and thus improve quality of life. Recent improved understanding of the process that leads to joint destruction means that regenerative therapies such as stem cells have a real place in the conservative treatment of this disabling condition.
Adult stem cells are found throughout the body. They multiply by cell division to replenish dying cells and regenerate damaged tissues. Scientific interest in adult stem cells is centred on their ability to divide or self-renew indefinitely, and generate all the cell types of the organ from which they originate, potentially regenerating the entire organ from a few cells. This means that introducing stem cells to a damaged joint could sees the release of cytokines, which are messenger proteins, that encourage cartilage growth, thus helping treat and modify the disease process occurring with osteoarthritis.
Clinical trials enable us to take a laboratory proven concept and thoroughly test and analyse the effectiveness of a treatment on patients affected by a certain condition. Within these tightly controlled trials we are able to determine whether these new treatments are safer and more effective than current accepted medicines/methods. Melbourne Stem Cell Centre trial protocols have prior and retrospective independent Human Research Ethics Committee approval and every patient is strictly followed-up to assess outcome/effectiveness of the treatment undertaken.